Quick Answer
Alto Neuroscience, Inc. reported Stockholders Equity of $151.14 million for fiscal year 2025.
Alto Neuroscience, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $151.14M | -0.2% |
| 2024 | $151.46M | +311.3% |
| 2023 | -$71.67M | -86.6% |
| 2022 | -$38.41M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $111.56M | -32.4% | -9.6% |
| June 30, 2025 | $123.41M | -31.4% | -11.3% |
| March 31, 2025 | $139.10M | -28.0% | -8.2% |
| December 31, 2024 | $151.46M | +311.3% | -8.2% |
| September 30, 2024 | $165.05M | +370.1% | -8.2% |
| June 30, 2024 | $179.78M | +441.8% | -6.9% |
| March 31, 2024 | $193.10M | +527.0% | +369.4% |
| December 31, 2023 | -$71.67M | -86.6% | -17.3% |
- Alto Neuroscience, Inc. showed a decrease of -0.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Alto Neuroscience, Inc.’s stockholders equity has grown by 493.5% (from -$38.41 million to $151.14 million).
- The most recent figure is from Alto Neuroscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: